Arcutis Biotherapeutics, Inc. (ARQT) — Financial statements
Income statement, balance sheet, and cash flow for Arcutis Biotherapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 376↑91.3% | 197↑229.7% | 60↑1517.1% | 4 | 0.00 | |
| Cost of Revenue | 37↑91.8% | 19↑283.6% | 5↑561.4% | 0.75↓1.2% | 0.76 | |
| Gross Profit | 339↑91.3% | 177↑224.8% | 55↑1762.9% | 3↑484.3% | -0.76 | |
| Operating Expenses | ||||||
| R&D Expenses | 77↑0.8% | 76↓30.9% | 111↓39.4% | 182↑25.3% | 146 | |
| General & Administrative Expenses | 0.00↓100.0% | 222 | 0.00↓100.0% | 122↑100.3% | 61 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 7 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 275↑19.7% | 229↑23.9% | 185↑51.6% | 122↑100.3% | 61 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.17 | |
| Operating Expenses | 352↑15.0% | 306↑3.4% | 296↓2.9% | 305↑48.0% | 206 | |
| Total Costs & Expenses | 388↑19.5% | 325↑8.1% | 301↓1.5% | 305↑47.8% | 207 | |
| Operating Results | ||||||
| Operating Income | -12↑90.5% | -128↑46.7% | -241↑20.1% | -302↓46.0% | -207 | |
| Depreciation & Amortization | 5↑106.5% | 3↑38.2% | 2↑50.1% | 1↑64.2% | 0.76 | |
| EBITDA | 2↑102.3% | -110↑51.8% | -227↑22.8% | -295↓43.3% | -206 | |
| EBIT | -3↑97.4% | -112↑51.1% | -229↑22.5% | -296↓43.3% | -206 | |
| Interest & Other Income | ||||||
| Net Interest Income | -12↑55.5% | -27↑8.6% | -30↓89.8% | -16↓9147.4% | 0.17 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.17 | |
| Interest Expense | 12↓55.5% | 27↓8.6% | 30↑89.8% | 16 | 0.00 | |
| Non-Operating Income | -9↑42.2% | -16↓37.2% | -12↓102.5% | -6↓3264.7% | -0.17 | |
| Other Income / Expenses | -3↑75.1% | -11↑38.7% | -18↓82.3% | -10↓5782.7% | 0.17 | |
| Income Before Tax | -15↑89.3% | -139↑46.2% | -259↑16.8% | -311↓50.9% | -206 | |
| Income Tax Expense | 1↑81.0% | 0.65↓79.2% | 3 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -16↑88.5% | -140↑46.6% | -262↑15.8% | -311↓50.9% | -206 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -16↑88.5% | -140↑46.6% | -262↑15.8% | -311↓50.9% | -206 | |
| Bottom-Line Net Income | -16↑88.5% | -140↑46.6% | -262↑15.8% | -311↓50.9% | -206 | |
| EPS (Basic) | -0.13↑88.8% | -1.16↑69.3% | -3.78↑33.2% | -5.66↓35.7% | -4.17 | |
| EPS (Diluted) | -0.13↑88.8% | -1.16↑69.3% | -3.78↑33.2% | -5.66↓35.7% | -4.17 | |
| Weighted Average Shares | 127↑5.2% | 121↑74.5% | 69↑25.9% | 55↑11.4% | 49 | |
| Weighted Average Diluted Shares | 127↑5.2% | 121↑74.5% | 69↑25.9% | 55↑11.4% | 49 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.